

Metropolis Healthcare Ltd. posts 7% YoY growth in Revenue to Rs. 293 crores

Non-Covid revenue grew by 9% YoY to Rs. 244 crores

- Patient visits increased by 22% on YoY basis to 3.3 Mn in Q3FY22
- No. of tests increased by 24% on YoY basis to 6.3 Mn in Q3FY22
- Home-Visits test services now covered in more than 100 locations
- Declared interim dividend of Rs. 8 per share

Mumbai, February 11, 2022: Metropolis Healthcare Ltd. (NSE: METROPOLIS | BSE: 542650) - a leading diagnostic service provider - announced its unaudited consolidated financial results today for the third quarter (Q3FY22).

Q3FY22 Financial Highlights

27.5%

EBITDA Margin
(Before CSR, ESOP & One-time acquisition cost)

+25% YoY

B2C Revenue Growth
(Non-Covid)

Rs. 41.2 Crs.

Reported PAT

“During Q3FY22, we are pleased to share that we have been able to grow our non-covid revenue despite sharp drop in volumes from a government contract. We have made increased investments in digital & marketing, manpower & customer experience initiatives in order to strengthen our brand. This has impacted margins which we believe is a short-term phenomenon.

Our focused cities performance and B2C contribution continues to witness healthy growth and is a testimony to our on-ground efforts and the acceptance of Metropolis Brand in the minds of consumers.

We have also been able to successfully complete the acquisition of Hitech Diagnostics during Q3 which will enable us to scale up our business, improve the B2C revenue contribution and tap the value end of the market.”

Ameera Shah, Promoter and Managing Director, Metropolis Healthcare Ltd.

ACCREDITATIONS FOR METROPOLIS

The Global Reference Laboratory of Metropolis holds accreditation from the College of American Pathologists (CAP) since 2005 which is the gold standard in accreditations in our industry, globally.

Our clinical laboratories hold one or more of CAP, NABL, KENAS, ILAC or APLAC accreditations.

(CAP: College of American Pathologists; NABL: National Accreditation Board for Testing and Calibration Laboratories; KENAS: Kenya Accreditation Service; ILAC: International Laboratory Accreditation Cooperation, APLAC: Asia Pacific Laboratory Accreditation Cooperation)

RECENT AWARDS AND ACCOLADES

Our MD Ms. Ameera Shah has won the Women Entrepreneur Award in Organizational Segment - Health & Wellness category at the Express Awards for Women Entrepreneurs (ExpressAWE), instituted by the Financial Express and FICCI FLO.

Our MD Ms. Ameera Shah has been featured among the 'Most Powerful Women in Business in India' in 2021 by Business Today for the third time.

Our MD, Ms. Ameera Shah has been featured among the Most Powerful Women in Business in 2021 by Fortune India for the fifth consecutive year.

Our MD, Ms. Ameera Shah won the prestigious Entrepreneur of the Year Award by EY in Lifesciences and Healthcare category

Metropolis Healthcare Ltd won the 2020 Indian Diagnostic Services Industry Company of the Year Award organised by Frost & Sullivan.

Metropolis Healthcare won the award for Outstanding Logistics Unit during Pandemic award in the Healthcare Category organised by Supply Chain and Logistics Excellence (SCALE) Awards

Metropolis won five different awards for its CSR Projects from different reputed CSR platforms.

Our CFO, Mr. Rakesh Agarwal was awarded at the 11th Annual CFO Awards for his exceptional contribution to the world of finance.

In INR Crs.	Q3FY22	Q3FY21
Revenue from Operations	293.1	274.7
EBIDTA (before CSR, ESOP & one-time acquisition cost)	80.5	90.2
EBIDTA margin (before CSR, ESOP & one-time acquisition cost)	27.5%	32.8%
Reported Profit After Tax	41.2	58.6
Reported PAT Margin (%)	14.1%	21.3%

About Metropolis: Metropolis Healthcare Ltd is a leading diagnostics company in India with a widespread presence across 20 states in India. Metropolis touches millions of lives each year by providing actionable health insights to patients and doctors. Metropolis offers a comprehensive range of 4000 plus tests and profiles that include advanced tests in diagnosis of cancer, neurological disorders, infectious diseases, and an array of genetic abnormalities. Metropolis' commitment to quality and accuracy in each test is reinforced by its consistent CAP proficiency score of more than 98% over the past decade, which places it amongst the top 1% laboratories worldwide for quality assurance. Metropolis philosophy rests on the pillars of technological superiority, a warm patient centric approach and reliable diagnostic reports. For more, please visit www.metropolisindia.com or click on [Twitter](#), [Facebook](#), or [LinkedIn](#).

Safe harbor statement

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors.

For further details please contact:

Company: Metropolis Healthcare Ltd.

CIN -L73100MH2000PLC192798

Mr. Jeyasingh Balakrishnan – Head PR and Corporate Communications

jeyasingh.b@metropolisindia.com

www.metropolisindia.com

Investor Relations Advisors: Strategic Growth Advisors Pvt. Ltd.

CIN: U74140MH2010PTC204285

Mr. Shogun Jain / Mr. Shrenik Shah

shogun.jain@sgapl.net / shrenik.shah@sgapl.net